http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4346307-B2

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
filingDate 2001-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-4346307-B2
titleOfInvention Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
abstract The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a):or a pharmaceutically acceptable salt thereof, wherein R<1>, R<4a>, R<4b>, R<5>, R<6>, R<7>, R<8>, R<9>, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009215304-A
priorityDate 2000-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15560
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397432
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID428707
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID407230
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410342298
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466325649
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29595
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403882
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID467355
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3356
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25187
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID473740
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15558
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID428070
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID613032
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9949120
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID560808
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID450240
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3358

Total number of triples: 52.